Şunu aradınız:: insuffi jenza (Maltaca - İngilizce)

pazjenti b’ insuffi jenza epatika
patients with hepatic insufficiency no dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency.

jenza akuta renali.
investigations very common:

tesavel ma iex studjat f’ pazjenti b’ insuffi jenza epatika.
tesavel has not been studied in patients with severe hepatic insufficiency.

ċ jenza l-fażi ta’ żvilupp u validazzjoni.
ic ts of interest in the development and validation phase.

e ƒ ċ jenza akbar tippermetti li jkun hemmanqas spejjeż.
greater efficiency allows for lower costs.

esperjenza minn studji klini i b’ tesavel f’ pazjenti b’ insuffi jenza renali moderata jew qawwija hi limitata.
clinical study experience with tesavel in patients with moderate or severe renal insufficiency is limited.

ipotenjoni u/jew insuffi ċjenza tal-qalb tmur għall-agħar
hypotension and/or worsening heart failure

in- numru ta ’ pazjenti b’ insuffi jenza renali moderata jew severa kien baxx wisq biex l- u u ming ajr periklu ta '
the number of patients with moderate to severe renal insufficiency was too low to confirm safe use of sitagliptin in this type of patients.

l- insuffi jenza tal- kliewi – inqas minn 6% tad- do a totali titne a mill - isem fl- awrina.
renal insufficiency - less than 6% of the total dose is eliminated in urine.

il- metaboli mu jista ’ jkollu sehem iktar sinifikanti fl- eliminazzjoni ta ’ sitagliptin fil- ka ta ’ insuffi jenza renali qawwija jew esrd.
metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal insufficiency or esrd.

m’ hemmx g alfejn bidla fid- do a g al pazjenti li g andhom insuffi jenza epatika afifa jew moderata tesavel ma iex studjat f’ pazjenti b’ insuffi jenza epatika qawwija.
tesavel has not been studied in patients with severe hepatic insufficiency.

il - pazjenti g andhom ikunu osservati g al sinjali jew sintomi ta ’ insuffi jenza tal- qalb, jieda fil- pi u edima meta novomix 30 jintu a flimkien ma ’ pioglitazone.
patients should be observed for signs and symptoms of heart failure, weight gain and oedema when novomix 30 is used in combination with pioglitazone.

l-esper-jenza tagħna tagħti rwol partikolari lill-ue fit-trawwim tal-integrazzjoni reġjonali.
our experience gives the eu a particular role in fostering regional integration.

l-esper-jenza ta’ galileo tissuġġerixxi li l-approċċ għal dawn l-intrapriżi ġodda għandujkunippjanatsewwa urealistiku.
experience of galileo suggeststhattheapproachtothesenewventuresshouldbe well planned andrealistic.

meta jkun hemm insuffi ċjenza tal-kliewi, il-kilwa ma tipproduċix biżżejjed mill-ormon naturali eritropojetina li ta’ spiss tikkawża anemija.
in kidney failure, the kidney does not produce enough of the natural hormone erythropoietin which can often cause anaemia.

15 pazjenti b’ insuffi jenza renali ija tal- krejatinina [crcl] ≥50 ml/ min,, m’ hemmx g al pazjenti b’ insuffi jenza renali afifa (tne b onn bidla fid- do a ta ’ tesavel.
14 patients with renal insufficiency for patients with mild renal insufficiency (creatinine clearance [crcl] ≥ 50 ml/ min), no dosage adjustment for tesavel is required.